Jefferies cuts Zealand Pharma stock rating on catalyst timing

Jefferies downgraded Zealand Pharma (ZEAL) to Hold from Buy and cut its price target to DKK320 (from DKK505), citing weaker near-term visibility after disappointing Phase III survodutide results and reducing its success probability to 40% from 60%. Offsetting positives include advancement of petrelintide into Phase 3 with Roche after Phase 2 results showing double-digit weight loss and placebo-like tolerability, plus a Deutsche Bank price-target increase to DKK300 from DKK275 on positive survodutide trial data. Despite the downgrade, InvestingPro flags the stock as undervalued (P/E 3.13), with a “EXCELLENT” financial health score, keeping the net read cautious but not bearish.

Analysis

This is less a thesis break than a catalyst reset. For ZEAL, the market will increasingly price the equity as a long-duration biotech option, where the absence of a de-risking event over the next 2-4 quarters matters more than any stated long-term valuation. That usually compresses the multiple first and only later forces fundamental estimates down, which is why the near-term risk is underperformance versus catalyst-rich obesity names and the broader XBI basket.

Second-order, the Roche tie-up and survodutide/MASH optionality matter mainly through timing and economics, not just science. If partnership terms are modest or the next visible data window sits in 2026-2027, capital can rotate to names with either commercial cash flow or nearer readouts (NVO, LLY, VKTX), leaving ZEAL as a funding source for relative-value shorts. The key medium-term variable is whether the company can create an earlier valuation bridge through protocol disclosure, business development, or an accelerated Phase 3 timeline.

Contrarian view: the downgrade may be directionally right but tactically late if holders were already treating ZEAL as a multi-year call option. The low apparent valuation is not much of a floor if earnings are not the driver and the catalyst stack is thin; in that regime, duration, not earnings, sets the price. The thesis breaks if ZEAL pulls forward Phase 3 initiation, announces materially better partner economics, or delivers a new obesity update that reintroduces a 6-12 month catalyst path.

Key Decisions for Investors

• Short ZEAL versus long XBI for a beta-neutral expression over the next 6-10 weeks; thesis is catalyst vacuum and duration risk, with the trade invalidated by an announced acceleration of Phase 3 or BD monetization.
• If you want cleaner relative value, pair short ZEAL against long NVO: NVO has commercial cash flow and nearer-term execution optionality, while ZEAL’s rerating depends on 2026-2027 events. Cover if ZEAL prints a materially richer Roche update or unexpected clinical de-risking.
• Use a defined-risk put spread on ZEAL into any strength rather than outright shorting if borrow/liquidity are tight; target a 1-3 month window where multiple compression is most likely to occur before fundamentals can reassert.
• Add ZEAL to a catalyst calendar watchlist: Phase 3 start timing, Roche collaboration economics, and any MASH disclosure. If management gives a concrete earlier timeline, the bearish setup should be reconsidered immediately.